Bleeding Disorders Market By Disease Type, By Treatment Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
출혈성 질환 시장은 2022년 138억 달러로 평가되며, 2023년부터 2032년까지 연평균 6.6% 성장하여 2032년에는 260억 달러에 달할 것으로 추정됩니다.
출혈성 질환은 혈전이 제대로 형성되지 않는 것이 특징인 질환입니다. 혈전은 부상이나 외상 후 출혈을 막는 데 필수적입니다. 출혈성 질환은 경미한 부상에도 과도한 출혈을 유발할 수 있으며, 경우에 따라서는 내출혈을 유발할 수도 있습니다.
출혈성 질환은 혈액 내 특정 응고인자의 결핍 또는 기능 장애로 인한 비정상적인 출혈을 특징으로 하는 질환군입니다. 일반적으로 사람이 다치거나 상처를 입으면 신체는 혈전을 형성하여 출혈을 멈추게 합니다. 그러나 출혈성 질환을 앓고 있는 환자의 경우 이 과정이 손상되거나 결여되어 비정상적인 출혈이나 과다 출혈이 발생할 수 있습니다. 혈우병은 가장 잘 알려진 일반적인 출혈성 질환으로 주로 남성에게 발생하며 생명을 위협하는 심각한 출혈 에피소드를 유발할 수 있습니다. 폰 빌레브란트병도 흔한 출혈성 질환으로 남녀 모두에게 발생하며, 부상이나 수술 후 출혈이 오래 지속될 수 있습니다.
출혈성 질환 시장의 성장을 촉진하는 주요 요인으로는 출혈성 질환 치료의 급속한 발전, 혈우병 A, 혈우병 B 및 기타 출혈성 질환을 앓고 있는 환자 수의 증가 등이 있습니다. 예를 들어, 미국 질병예방통제센터(CDC) 2022에 따르면, 미국에서는 33,000명의 남성이 출혈성 질환을 앓고 있습니다.
또한, 혈우병 관리에 대한 정부의 적극적인 노력, 출혈성 질환 치료에 대한 인식 제고 프로그램 증가, 항혈우병 치료제 개발을 위한 임상시험의 증가는 출혈성 질환 시장의 성장을 촉진하고 있습니다. 또한, 대상 인구의 증가, 진단율 증가, 혈우병 예방 치료의 급증은 시장 성장을 촉진하고 있습니다.
그러나 혈우병 치료의 높은 비용과 혈장 유래 제품과 관련된 심각한 부작용은 출혈성 질환 시장의 성장을 제한할 것으로 예상됩니다. 반면, 의료비 지출의 급증과 신흥국에서 혈우병에 대한 더 나은 치료 옵션을 얻기 위한 충족되지 않은 의료 수요는 향후 세계 시장 확대의 엄청난 기회를 창출할 것으로 예상됩니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 개요
- 시장 정의와 범위
- 주요 조사 결과
- Porter's Five Forces 분석
- 공급 기업의 교섭력
- 구매자의 교섭력
- 대체품의 위협
- 신규 참여업체의 위협
- 경쟁의 강도
- 시장 역학
- 성장 촉진요인
- 혈우병 유병률 상승
- 혈우병 치료의 기술적 진보
- 혈우병 관리에 대한 정부 적극적인 대처
- 성장 억제요인
- 기회
- COVID-19의 시장에 대한 영향 분석
제4장 출혈성 질환 시장 : 질환 유형별
- 개요
- 혈우병 A
- 혈우병 B
- 폰빌레브란트병
- 기타
제5장 출혈성 질환 시장 : 치료 유형별
제6장 출혈성 질환 시장 : 유통 채널별
- 개요
- 병원 약국
- 드럭스토어 및 소매 약국
- 온라인 약국
제7장 출혈성 질환 시장 : 지역별
- 개요
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카, 중동 및 아프리카
- 브라질
- 사우디아라비아
- 남아프리카공화국
- 기타 지역
제8장 경쟁 상황
- 서론
- 주요 성공 전략
- 주요 10개 기업의 제품 매핑
- 경쟁 대시보드
- 경쟁 히트맵
- 주요 기업의 포지셔닝, 2022년
제9장 기업 개요
- Pfizer Inc.
- Novo Nordisk A/S
- Bayer AG
- Octapharma AG
- Sanofi
- Medexus Pharma, Inc.
- Grifols, S.A.
- F. Hoffmann-La Roche Ltd.
- CSL Limited
- Takeda Pharmaceutical Company Limited
KSM
According to a new report published by Allied Market Research, titled, "Bleeding Disorders Market," The bleeding disorders market was valued at $13.8 billion in 2022, and is estimated to reach $26 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032. A bleeding disorder is a medical condition characterized by inability of a person to form blood clots properly. Blood clots are essential in stopping bleeding after an injury or trauma. Bleeding disorders may lead to excessive bleeding, even with minor injuries, and may also cause internal bleeding in some cases.
Bleeding disorders are a group of conditions characterized by abnormal bleeding due to the deficiency or dysfunction of certain clotting factors in the blood. Normally, when a person experiences an injury or cut, the body forms a clot to stop bleeding. However, in a person with a bleeding disorder, this process is impaired or absent, which may lead to abnormal or excessive bleeding. Hemophilia is the most well-known and common bleeding disorder, which affects mostly males and may result in serious and life-threatening bleeding episodes. Von Willebrand disease is another common bleeding disorder that affects both males and females and may lead to prolonged bleeding after injury or surgery.
Major factors that drive the growth of the bleeding disorders market include rapid advancements in treatment of bleeding disorders; increase in number of patients suffering from hemophilia A, hemophilia B, and other bleeding disorders. For instance, according to the Centers for Disease Control and Prevention (CDC) 2022, 33,000 males in the U.S. live with the bleeding disorder.
Furthermore, favorable government initiatives for hemophilia management, increase in number of awareness programs regarding bleeding disorder treatment and rise in number of clinical trials for the development of antihemophilic drugs boost the growth of bleeding disorders market. In addition, the increase in target population, increase in diagnosis rate, and surge in the use of prophylactic treatment for hemophilia propel the market growth.
However, the high cost of hemophilia treatment, and serious adverse effects associated with plasma derived products are expected to restrict the growth of bleeding disorders market. On the contrary, surge in healthcare expenditure, and unmet medical demands to get better treatment options for hemophilia in developing countries are expected to create immense opportunities for the expansion of the global market in the future.
The bleeding disorders market is segmented on the basis of disease type, treatment type, distribution channel and region. On the basis of disease type, the market is classified into hemophilia A, hemophilia B, Von Willebrand disease and others. On the basis of treatment type, the market is classified into factor replacement therapy, and drug therapy (desmopressin, antifibrinolytics, fibrin sealant). The factor replacement therapy segment is further bifurcated into plasma-derived coagulation factor concentrates, and recombinant coagulation factor concentrates. On the basis of distribution channel, the bleeding disorders market is segmented into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major players profiled in the report are Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A., Medexus Pharma, Inc., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., SANOFI CORPORATION, and Takeda Pharmaceutical Company Limited. The major players in the market have adopted investment, partnership and product approvals as key developmental strategies to improve the product portfolio of the bleeding disorders market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bleeding disorders market analysis from 2022 to 2032 to identify the prevailing bleeding disorders market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the bleeding disorders market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global bleeding disorders market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
By Treatment Type
- Factor Replacement Therapy
- Type
- Recombinant coagulation factor concentrates
- Plasma derived coagulation factor concentrates
- Drug Therapy
By Distribution Channel
- Hospital Pharmacies
- Drug stores and retail pharmacies
- Online pharmacies
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Medexus Pharma, Inc.
- Bayer AG
- Novo Nordisk A/S
- Grifols, S.A.
- Octapharma AG
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Pfizer Inc.
- Sanofi
- F. Hoffmann-La Roche Ltd.
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of hemophilia
- 3.4.1.2. Technological advancements in treatment of hemophilia
- 3.4.1.3. Favorable government initiatives for hemophilia management
- 3.4.2. Restraints
- 3.4.2.1. High cost of bleeding disorders treatments
- 3.4.3. Opportunities
- 3.4.3.1. Rise in awareness about bleeding disorders in developing countries
- 3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: BLEEDING DISORDERS MARKET, BY DISEASE TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Hemophilia A
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Hemophilia B
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Von Willebrand Disease
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
CHAPTER 5: BLEEDING DISORDERS MARKET, BY TREATMENT TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Factor Replacement Therapy
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.2.4. Factor Replacement Therapy Bleeding Disorders Market by Type
- 5.3. Drug Therapy
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
CHAPTER 6: BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Drug stores and retail pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
CHAPTER 7: BLEEDING DISORDERS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Disease Type
- 7.2.3. Market size and forecast, by Treatment Type
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Disease Type
- 7.2.5.1.3. Market size and forecast, by Treatment Type
- 7.2.5.1.4. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Disease Type
- 7.2.5.2.3. Market size and forecast, by Treatment Type
- 7.2.5.2.4. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Disease Type
- 7.2.5.3.3. Market size and forecast, by Treatment Type
- 7.2.5.3.4. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Disease Type
- 7.3.3. Market size and forecast, by Treatment Type
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Disease Type
- 7.3.5.1.3. Market size and forecast, by Treatment Type
- 7.3.5.1.4. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Disease Type
- 7.3.5.2.3. Market size and forecast, by Treatment Type
- 7.3.5.2.4. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Disease Type
- 7.3.5.3.3. Market size and forecast, by Treatment Type
- 7.3.5.3.4. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Disease Type
- 7.3.5.4.3. Market size and forecast, by Treatment Type
- 7.3.5.4.4. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Disease Type
- 7.3.5.5.3. Market size and forecast, by Treatment Type
- 7.3.5.5.4. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Disease Type
- 7.3.5.6.3. Market size and forecast, by Treatment Type
- 7.3.5.6.4. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Disease Type
- 7.4.3. Market size and forecast, by Treatment Type
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Disease Type
- 7.4.5.1.3. Market size and forecast, by Treatment Type
- 7.4.5.1.4. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Disease Type
- 7.4.5.2.3. Market size and forecast, by Treatment Type
- 7.4.5.2.4. Market size and forecast, by Distribution Channel
- 7.4.5.3. Australia
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Disease Type
- 7.4.5.3.3. Market size and forecast, by Treatment Type
- 7.4.5.3.4. Market size and forecast, by Distribution Channel
- 7.4.5.4. India
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Disease Type
- 7.4.5.4.3. Market size and forecast, by Treatment Type
- 7.4.5.4.4. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Disease Type
- 7.4.5.5.3. Market size and forecast, by Treatment Type
- 7.4.5.5.4. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Disease Type
- 7.4.5.6.3. Market size and forecast, by Treatment Type
- 7.4.5.6.4. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Disease Type
- 7.5.3. Market size and forecast, by Treatment Type
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Disease Type
- 7.5.5.1.3. Market size and forecast, by Treatment Type
- 7.5.5.1.4. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Disease Type
- 7.5.5.2.3. Market size and forecast, by Treatment Type
- 7.5.5.2.4. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Disease Type
- 7.5.5.3.3. Market size and forecast, by Treatment Type
- 7.5.5.3.4. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Disease Type
- 7.5.5.4.3. Market size and forecast, by Treatment Type
- 7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
- 9.1. Pfizer Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Novo Nordisk A/S
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Bayer AG
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Octapharma AG
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Sanofi
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Medexus Pharma, Inc.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Grifols, S.A.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. F. Hoffmann-La Roche Ltd.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. CSL Limited
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Takeda Pharmaceutical Company Limited
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
